American startup Synchron has launched clinical trials of the Stentrode brain-computer interface designed to assist patients with stroke. He writes about Bloomberg.

We are proud to announce that we have reached an important milestone for our company and the millions of people who live together. #paralysis. We have officially enrolled the first patient of our early feasibility study in the USA. To learn more https://t.co/vHRYtUx9z3 pic.twitter.com/XWtwhi6kS4n

— synchronous (@synchroninc) May 4, 2022

The experiment will involve six patients from New York and Pittsburgh, Pennsylvania. One of them has already reached the hospital, but Synchron founder and CEO Tom Oxley has declined to name him or provide demographic data.

At the first stage, the Stentrode must verify its security and provide the ability to control digital devices without the help of hands.

Prior to this, Synchron received approvals for short-term laboratory work. The company believes that if the test is successful, the device could be approved for widespread use in the long term.

Recall that in January Neuralink Elon Musk opened a vacancy for clinical research director.

That same month, scientists developed an AI-powered eye implant that restores the sight of a nearly blind woman.

In August 2021, Synchron received approval from the US Food and Drug Administration to conduct human testing of neural interfaces.